Gabapentin Capsule
Product Images NDC 71335-1197

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

Gabapentin-equation (Gabapentin Equation)
A text panel displaying the formula for calculating creatinine clearance (CLCr), including adjustments for female patients. The formula uses age, weight, serum creatinine, and a gender-specific factor.*
FDA Label Image

Structure (Gabapentin Fig 5)

Structure (Gabapentin Fig 5)
Chemical structure of gabapentin, showing a cyclohexane ring attached to two side groups: CH2NH2 and CH2CO2H.*
FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

Gabapentin-fig1 (Gabapentin Fig1)
A line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The horizontal axis represents weeks with distinctions between a 4-week dose titration period and a 4-week fixed dose period. The vertical axis shows mean pain scores from 0 to 10, illustrating a decline in pain scores for gabapentin compared to placebo over time.*
FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

Gabapentin-fig2 (Gabapentin Fig2)
Line graph depicting mean pain scores over 7 weeks for placebo and two gabapentin dosages (1800 mg/day and 2400 mg/day). The graph shows a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for gabapentin groups compared to placebo.*
FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

Gabapentin-fig3 (Gabapentin Fig3)
A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600. Study 2 shows 14% responders for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is indicated with p-values less than 0.01 and 0.001.*
FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

Gabapentin-fig4.jpg (Gabapentin Fig4)
A chart showing percentage difference plotted against daily dose in mg (600 to 1800 mg) for three studies labeled a, b, and c. The chart uses squares filled with different colors representing each study: black for study a, gray for study b, and white for study c. Data points show increasing percentage differences with higher daily doses across the studies.*
FDA Label Image

Label (Lbl713351197)

Label (Lbl713351197)
Gabapentin Capsules, USP 300 mg oral capsules, repackaged by Bryant Ranch Prepack and manufactured by Alkem Laboratories Ltd. This package contains 30 capsules. The label includes storage instructions, child-resistant container information, a QR code for prescribing information, and a barcode. The product is labeled Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.